ALPN News and Press, Alpine Immune Sciences Inc. From 08/11/22

Alpine Immune Sciences press release ( NASDAQ: ALPN ): Q2 GAAP EPS of -$0.60 misses by $0.21 . Revenue of $5.29M (-26.4% Y/Y) misses by $4.75M . For further details see: Alpine Immune Sciences GAAP EPS of -$0.60 misses by $0.21, revenue of $5.29M misses b...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June...

- Just – Evotec Biologics will apply its fully integrated technology platform to develop an optimized commercial process for ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases - Evotec SE (Frankfurt St...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at the 2022 Wedbush PacGrow Healthc...

- 20-year industry veteran with extensive global clinical development leadership experience in autoimmune and inflammatory diseases - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for ca...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Alpine Immune Sciences (NASDAQ:ALPN) appoints industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer effective August 17, 2022. Most recently Dr. Sandler was the Chief Medical Officer of  Kiadis Pharma, a Sanofi Company. “I am thrilled to join the Al...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical O...

- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc’s - - Ongoing phase 1 study demonstrates highly encouraging preliminary pharmacodynamic reductions in circulating immunoglobulins - ...

Studies suggest that index rebalancing anomalies generate excess risk-adjusted returns caused by stock index funds and institutional investors that benchmark the indexes. Four years of research including the most robust 2021 study come to a close on the annual June rebalancing and som...